gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

CD22 molecule

Top mentioned proteins: CD20, CD19, CAN, HAD, CD5
Papers using CD22 antibodies
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
McCubrey James, In PLoS ONE, 2008
... Cruz Biotechnology), anti-HIF-1α (BD Biosciences), FITC-conjugated mouse monoclonal anti-PIM (HPI, Inc), anti-CD45 (Cell Signaling Technology), anti-CD22 (Novocastra), anti-CXCR4 (Abcam), anti-SDF-1α, anti-CD31 (Santa Cruz ...
B cell antigen receptor signal strength and peripheral B cell development are regulated by a 9-O-acetyl sialic acid esterase
Pillai Shiv et al., In The Journal of Experimental Medicine, 2006
... CD22 regulates thymus-independent responses and the lifespan of B cells ...
Papers on CD22
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
Jain et al., Houston, United States. In Immunotherapy, Feb 2016
UNASSIGNED: Inotuzumab ozogamicin is a humanized anti-CD22 monoclonal antibody bound to a toxic natural calicheamicin, which is under investigation for the treatment of relapsed/refractory acute lymphoblastic leukemia.
Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
Jabbour et al., Houston, United States. In Expert Rev Hematol, Feb 2016
UNASSIGNED: Over 90% of leukemic blasts in patients with acute lymphoblastic leukemia express the marker CD22.
Versatile strategy for controlling the specificity and activity of engineered T cells.
Cao et al., Los Angeles, United States. In Proc Natl Acad Sci U S A, Feb 2016
Here, we describe the design and synthesis of structurally defined semisynthetic adaptors we refer to as "switch" molecules, in which anti-CD19 and anti-CD22 antibody fragments are site-specifically modified with FITC using genetically encoded noncanonical amino acids.
Sialic acids and autoimmune disease.
Pillai et al., Cambridge, United States. In Immunol Rev, Jan 2016
The inhibitory functions of CD22/Siglec-2 and Siglec-G and their contributions to tolerance and autoimmunity, primarily in the B lymphocyte context, are considered in some detail in this review.
Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia.
Marks et al., Bristol, United Kingdom. In Expert Rev Anticancer Ther, Jan 2016
Inotuzumab ozogamicin (previously known as CMC-544) is an antibody-drug conjugate and consists of a monoclonal anti-CD22 antibody bound to calicheamicin.
The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia.
DeAngelo, Boston, United States. In Hematology Am Soc Hematol Educ Program, Jan 2016
Several approaches have been used to target antigens, including cluster of differentiation (CD) 19, CD20, CD22, and CD52, on the surface of the malignant lymphoblast with striking efficacy.
The PPI network and clusters analysis in glioblastoma.
Ma et al., Chengdu, China. In Eur Rev Med Pharmacol Sci, Dec 2015
LYN, CD22 and LCP2 form a densely protein complex in the PPI network.
Intravital imaging of Ca(2+) signals in lymphocytes of Ca(2+) biosensor transgenic mice: indication of autoimmune diseases before the pathological onset.
Adachi et al., Tokyo, Japan. In Sci Rep, Dec 2015
Furthermore, in autoimmune-prone models, the CD22(-/-) and C57BL/6- lymphoproliferation (lpr)/lpr mouse, Ca(2+) fluxes were augmented, although they did not induce autoimmune disease.
Immunoconjugates in the management of hairy cell leukemia.
Pastan et al., Bethesda, United States. In Best Pract Res Clin Haematol, Dec 2015
Recombinant immunotoxins tested in HCL patients include LMB-2, targeting CD25, and BL22, targeting CD22.
Full Expression of Cardiomyopathy Is Partly Dependent on B-Cells: A Pathway That Involves Cytokine Activation, Immunoglobulin Deposition, and Activation of Apoptosis.
Torre-Amione et al., Houston, United States. In J Am Heart Assoc, Dec 2015
Mice (12 weeks old) were divided into 4 groups, all in C57BL/6 background: wild-type (WT) CMP; severe combined immunodeficiency (SCID) CMP (T- and B-cell deficient); CD22(-) CMP (B-cell depleted); and Nude CMP (T-cell deficient), with their respective controls.
Transcriptional programs of lymphoid tissue capillary and high endothelium reveal control mechanisms for lymphocyte homing.
Butcher et al., Stanford, United States. In Nat Immunol, 2014
We also elucidate a carbohydrate-recognition pathway that targets B cells to intestinal lymphoid tissues, defining CD22 as a lectin-homing receptor for mucosal HEVs.
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Dang et al., Houston, United States. In J Clin Oncol, 2013
PURPOSE: Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent.
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
Pastan et al., Bethesda, United States. In J Clin Oncol, 2012
Anti-CD22 recombinant immunotoxin moxetumomab pasudotox has activity in relapsed/refractory hairy cell leukemia.
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
O'Brien et al., Houston, United States. In Lancet Oncol, 2012
CD22 is highly expressed in patients with ALL.
The pan-B cell marker CD22 is expressed on gastrointestinal eosinophils and negatively regulates tissue eosinophilia.
Rothenberg et al., Cincinnati, United States. In J Immunol, 2012
novel expression pattern and tissue eosinophilia-regulating function for the "B cell-specific" inhibitory molecule CD22 on GI eosinophils.
CD22 serves as a receptor for soluble IgM.
Tedder et al., Tokyo, Japan. In Eur J Immunol, 2012
As a receptor for sIgM, CD22 induces a negative feedback loop for B-cell activation/
CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia.
Uckun et al., Los Angeles, United States. In Br J Haematol, 2012
Our study implicates the CD22DeltaE12 genetic defect in the aggressive biology of relapsed or therapy-refractory paediatric B-lineage ALL.
Association study of B-cell marker gene polymorphisms in European Caucasian patients with systemic sclerosis.
Allanore et al., Paris, France. In Clin Exp Rheumatol, 2011
Results obtained through a large cohort of European caucasian patients with systemic sclerosis do not support the contribution of CD19, CD20, CD22, CD24 variants to the genetic susceptibility.
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
Goldenberg et al., Lille, France. In J Clin Oncol, 2010
PURPOSE: Fractionated radioimmunotherapy targeting CD22 may substantially improve responses and outcome in non-Hodgkin's lymphoma (NHL).
share on facebooktweetadd +1mail to friends